Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFSNASDAQ:LQDANASDAQ:NYXHNASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$22.40-3.0%$23.71$18.70▼$29.55$1.07B2.01379,508 shs75,194 shsLQDALiquidia$17.32+8.3%$14.25$8.26▼$17.34$1.48B0.241.00 million shs493,617 shsNYXHNyxoah$5.78+0.0%$7.43$5.55▼$12.21$197.04M1.5670,681 shs30,435 shsTNDMTandem Diabetes Care$23.24+0.5%$18.75$15.75▼$53.69$1.55B1.471.50 million shs153,642 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions-3.35%+5.28%+5.43%-12.34%+11.76%LQDALiquidia+1.52%+2.68%+18.71%-1.60%+31.71%NYXHNyxoah-3.34%-9.69%-6.02%-45.00%-34.69%TNDMTandem Diabetes Care-1.36%+8.49%+35.58%-29.72%-47.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLFSBioLife Solutions2.4695 of 5 stars3.51.00.00.03.42.50.6LQDALiquidia2.5921 of 5 stars3.60.00.00.03.04.20.6NYXHNyxoah3.0208 of 5 stars3.55.00.00.03.00.80.6TNDMTandem Diabetes Care4.7586 of 5 stars4.34.00.04.93.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.00Buy$31.1739.14% UpsideLQDALiquidia 3.11Buy$27.1356.61% UpsideNYXHNyxoah 3.00Buy$14.50150.82% UpsideTNDMTandem Diabetes Care 2.53Moderate Buy$39.8171.30% UpsideCurrent Analyst Ratings BreakdownLatest NYXH, TNDM, LQDA, and BLFS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025BLFSBioLife SolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/12/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/12/2025LQDALiquidiaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/9/2025LQDALiquidiaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$27.00 ➝ $29.005/5/2025LQDALiquidiaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/5/2025LQDALiquidiaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$34.00 ➝ $36.005/1/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $59.005/1/2025TNDMTandem Diabetes CareStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $31.005/1/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$22.00 ➝ $20.005/1/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$36.00 ➝ $30.005/1/2025TNDMTandem Diabetes CareRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$33.00 ➝ $24.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$87.76M12.12N/AN/A$7.67 per share2.92LQDALiquidia$14.14M104.68N/AN/A$0.73 per share23.73NYXHNyxoah$4.52M43.55N/AN/AN/A∞TNDMTandem Diabetes Care$982.95M1.57N/AN/A$4.81 per share4.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$66.43M-$0.29N/AN/AN/A-38.98%-6.61%-5.54%N/ALQDALiquidia-$78.50M-$1.58N/AN/AN/A-765.38%-163.21%-67.14%N/ANYXHNyxoah-$46.77M-$1.95N/AN/AN/A-1,043.93%-51.68%-40.11%5/14/2025 (Estimated)TNDMTandem Diabetes Care-$222.61M-$2.78N/AN/AN/A-14.84%-44.19%-11.99%N/ALatest NYXH, TNDM, LQDA, and BLFS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025NYXHNyxoah-$0.49-$0.63-$0.14-$0.63$1.64 millionN/A5/8/2025Q1 2025BLFSBioLife Solutions-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 million5/8/2025Q1 2025LQDALiquidia-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million4/30/2025Q1 2025TNDMTandem Diabetes Care-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 million3/19/2025Q4 2024LQDALiquidia-$0.38-$0.46-$0.08-$0.46$4.60 million$2.92 million3/13/2025Q4 2024NYXHNyxoah-$0.46-$0.49-$0.03-$0.49$2.02 million$1.35 million3/3/2025Q4 2024BLFSBioLife Solutions-$0.06$0.26+$0.32$0.26$21.73 million$22.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/ALQDALiquidiaN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife Solutions0.032.781.78LQDALiquidiaN/A6.336.33NYXHNyxoah0.215.284.95TNDMTandem Diabetes Care1.292.902.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%LQDALiquidia64.54%NYXHNyxoahN/ATNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%LQDALiquidia30.10%NYXHNyxoah17.11%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.50 million45.37 millionOptionableLQDALiquidia5085.49 million59.16 millionOptionableNYXHNyxoah11034.06 million28.23 millionNot OptionableTNDMTandem Diabetes Care2,60066.61 million64.23 millionOptionableNYXH, TNDM, LQDA, and BLFS HeadlinesRecent News About These CompaniesJacobs Levy Equity Management Inc. Increases Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 14 at 5:57 AM | marketbeat.comTandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion setMay 13 at 3:53 PM | drugdeliverybusiness.comNorthern Trust Corp Purchases 61,768 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 13 at 3:48 AM | marketbeat.comTandem Diabetes Care: Promising Growth Driven by Robust Pipeline and Strategic InitiativesMay 12 at 10:15 AM | tipranks.comFrontier Capital Management Co. LLC Has $9.80 Million Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 12 at 5:35 AM | marketbeat.comFred Alger Management LLC Sells 35,763 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 10, 2025 | marketbeat.comDAFNA Capital Management LLC Buys 19,000 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 10, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Algert Global LLCMay 10, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Divisadero Street Capital Management LPMay 9, 2025 | marketbeat.comBrevan Howard Capital Management LP Boosts Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 9, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives $39.81 Consensus Target Price from BrokeragesMay 9, 2025 | americanbankingnews.com913,087 Shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Bought by Brown Advisory Inc.May 8, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 8, 2025 | marketbeat.comFirst Trust Advisors LP Decreases Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 7, 2025 | marketbeat.comTandem Diabetes Care Announces Upcoming Conference PresentationsMay 6, 2025 | gurufocus.comTandem Diabetes Care Announces Upcoming Conference PresentationsMay 6, 2025 | businesswire.comBellevue Group AG Cuts Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 6, 2025 | marketbeat.comBeaconlight Capital LLC Has $11.93 Million Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 6, 2025 | marketbeat.comHsbc Holdings PLC Purchases 14,501 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 6, 2025 | marketbeat.comLeerink Partnrs Has Pessimistic Outlook of TNDM Q2 EarningsMay 6, 2025 | marketbeat.comArrowMark Colorado Holdings LLC Purchases 337,026 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNYXH, TNDM, LQDA, and BLFS Company DescriptionsBioLife Solutions NASDAQ:BLFS$22.40 -0.69 (-2.99%) As of 10:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.Liquidia NASDAQ:LQDA$17.32 +1.33 (+8.32%) As of 10:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Nyxoah NASDAQ:NYXH$5.78 +0.00 (+0.02%) As of 10:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Tandem Diabetes Care NASDAQ:TNDM$23.24 +0.11 (+0.48%) As of 10:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oklo Reaches Critical Mass, Atomic Upside Still Available U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer NVIDIA Stock Surges on Bullish News: How High Could It Climb? ON Holding Surges, Leads High-End Retailers Into Reversal D-Wave Pushes Back on Short Seller Case With Strong Earnings NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
